Treatment of Aggressive Pelvic Fibromatosis With Interferon

Obstet Gynecol. 2015 Dec;126(6):1219-1221. doi: 10.1097/AOG.0000000000001158.

Abstract

Background: Fibromatosis is a rare, noninvasive but aggressive tumor. The tumor displaces tissue by "pushing" the normal structures aside. Optimal treatment should be individualized.

Case: A 35-year-old woman presented with a recurrent fibromatosis, which filled the vagina and extended into the pelvis. The classical surgical removal would have had a high morbidity. Therefore, it was decided, after shared decision-making, to opt for treatment with interferon. The side effects of the therapy were tolerable, and a complete regression of the fibromatosis was achieved. At present, 13 years after the diagnosis and 7 years after discontinuation of the therapy, the patient is well with no signs of disease.

Conclusion: Interferon may be considered as primary treatment for extensive pelvic fibromatosis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Fibromatosis, Abdominal / drug therapy*
  • Fibromatosis, Abdominal / pathology
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Pelvis / pathology
  • Recombinant Proteins / therapeutic use
  • Vaginal Neoplasms / drug therapy*
  • Vaginal Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins